Dermatocosmetology: prospects in the treatment of psoriasis
What should and should not be done during psoriasis treatment?
Let's talk about a disease that some of your patients may be suffering from. After all, the main achievement in the treatment of psoriasis is not the invention of new drugs, but a real revolution in the doctor-patient relationship.
The number of psoriasis patients in the general population of our planet is on average about 2.5–3% (from 0.7% to 5% depending on the geography of residence). Of these, 25% of cases are moderate and severe forms of psoriasis that require systemic treatment.
The severity of the disease is assessed mainly by two criteria: impact on quality of life and area of involvement. Impact on quality of life is measured by scales, the most widely used of which is called DLQI (Dermatology Life Quality Index).
The area of the affected body is the percentage of the body surface affected by the disease to the total body surface area. If 10% to 30% of the skin is affected, we are talking about moderate forms of psoriasis. If more than 30% of the skin is affected, we are talking about severe forms of the disease.
Full version of the access article in Ukrainian